Malaysia is projected to gain RM 2.1 billion in Gross National Income (GNI) through 3500 sponsored clinical research that are to be conducted between years 2023-2033, according to Clinical Research Malaysia. These targets were unveiled under CRM’s 10-year plan, which were recently presented in the Clinical Research Governance World Conference at Hong Kong, attended by leading clinical research networks.
Clinical Research Malaysia (CRM), a Global Trusted Research Management Organisation (GTRMO) by the Ministry of Health was established since 2012 to accelerate the sponsored clinical research ecosystem within the country. Within the first decade of its establishment (2012 -2022), clinical research in the country has generated a revenue of over RM 1 billion in GNI from over 2000 clinical research recorded.
“CRM’s 10-year mission is focused with the organisation staying steadfast as a GTRMO and in having clinical research recognised as an industry that not only supports the healthcare system but one that contributes effectively to the country’s revenue. To support the growth of the industry, CRM is setting up a Centre of Excellence for graduates to gain a head start into their career in clinical research as well as digitalising our site management processes to stay ahead with global developments. Our vision is to make Malaysia the preferred clinical research hub in Asia by 2033”, added CRM’s Chief Executive Officer, Dr Akhmal Yusof.
Among its 2033 targets, CRM projects an expansion in early phase (Phase 1) clinical research within the country, foreseeing 80 Phase 1 studies to be conducted in Malaysia between 2023-2033. This is following the completion of CRM’s Phase 1 Realization Project (P1RP) and its continuation under P1RP 2.0, where now there have been heightened visibility by global organisations to conduct early phase trials, especially First-In-Human research in Malaysia. CRM also projects a growth in the country’s clinical research skilled workforce, to having 4000 clinical research professionals by year 2033, due to expansion of clinical research function by multinational organizations in Malaysia as more offices and teams are being setup to manage the growing number of trials in the country.
